Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
Conditions
Brief summary
This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tipifarnib may be an effective treatment for non-Hodgkin's lymphoma.
Detailed description
PRIMARY OBJECTIVES: I. To assess tumor response to R115777 (tipifarnib) in patients with relapsed aggressive non-Hodgkin's lymphoma. (Permanently closed to accrual 6/28/06) II. To assess tumor response to R115777 in patients with relapsed indolent non-Hodgkin's lymphoma. (Permanently closed to accrual 9/26/07) III. To assess tumor response to R115777 in patients with uncommon non-Hodgkin's lymphomas. IV. To evaluate toxicity associated with this regimen in patients with relapsed non-Hodgkin's lymphoma. SECONDARY OBJECTIVES: I. To evaluate known and unknown molecular markers that may predict for response to R115777 in lymphoma tissue. OUTLINE: Patients receive tipifarnib orally (PO) twice daily (BID) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for 2 years.
Interventions
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGTipifarnib
Given PO
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Biopsy-proven relapsed or refractory lymphomas; previous biopsies =\< 6 months prior to treatment on this protocol will be acceptable as long as there has not been intervening therapy; if the patient has received therapy for non-Hodgkin's disease (NHL) between the time of the last biopsy and this protocol, then a re-biopsy is necessary * STUDY 1: Aggressive lymphomas (permanently closed to accrual 6/28/06): * Transformed lymphomas * Diffuse large B cell lymphoma * Mantle cell lymphoma * Follicular lymphoma grade III STUDY 2: Indolent lymphomas (permanently closed to accrual 9/26/07) * Small lymphocytic lymphoma/chronic lymphocytic leukemia * Follicular lymphoma, grades 1, 2 * Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type * Nodal marginal zone B-cell lymphoma * Splenic marginal zone B-cell lymphoma STUDY 3: Uncommon lymphomas: * Peripheral T cell lymphoma, unspecified * Anaplastic large cell lymphoma (T and null cell type) * Lymphoplasmacytic lymphoma * Mycosis fungoides/ Sezary syndrome * Relapsed Hodgkin's disease (patients must be previously treated and either have had a transplant or not be eligible for a transplant) * Previously treated (no limitations on the number of prior therapies); patients with aggressive lymphoma (Study 1 - permanently closed to accrual 6/28/06) should have received or be ineligible for potentially curable therapy including stem cell transplant * MEASURABLE DISEASE: Must have at least one lesion that has a single diameter of \>= 2 cm or tumor cells in the blood \>= 5 x10\^9/L * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2 * Absolute neutrophil count \>=1000/mm\^3 * Platelet count \>= 75,000 * Hemoglobin \>= 9 g/dL * Total bilirubin =\< 2 x upper limit of normal (ULN) (if \> 2 x ULN direct bilirubin is required and should be =\< 1.5 x ULN) * Aspartate aminotransferase (AST) =\< 3 x ULN (=\< 5 x ULN if liver involvement is present) * Serum creatinine =\< 2 x ULN * Expected survival \>= 3 months * Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide valid informed consent * Capable of swallowing intact study medication tablets * Capable of following directions regarding taking study medication, or has a daily caregiver who will be responsible for administering study medication
Exclusion criteria
* Any of the following as this regimen may be harmful to a developing fetus or nursing child: * Pregnant women * Breastfeeding women * Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.) * NOTE: The effects of R115777 on the developing human fetus at the recommended therapeutic dose are unknown * Life-threatening illness (unrelated to tumor) * Ongoing radiation therapy or radiation therapy =\< 3 weeks prior to study registration unless the acute side effects associated with such therapy are resolved * Therapy with myelosuppressive chemotherapy, cytotoxic chemotherapy, or biologic therapy =\< 3 weeks (6 weeks for nitrosourea or mitomycin C) or corticosteroids =\< 2 weeks, prior to starting R11577; patients may be on corticosteroids or tapering off them up until the day they start R11577 as long as it is clear that they are not having a tumor response to the steroids or that the steroids would confuse the interpretation of response to R11577; patients may be receiving stable (not increased within the last month) chronic doses of corticosteroids with a maximum dose of 20 mg of prednisone per day if they are being given for disorders other than lymphoma such as rheumatoid arthritis, polymyalgia rheumatica, adrenal insufficiency, or intractable symptoms of lymphoma * Peripheral neuropathy \>= grade 3 * Serious non-malignant disease such as active infection or other condition which in the opinion of the investigator would compromise other protocol objectives * Presence of central nervous system (CNS) lymphoma * Other active malignancies * Once a patient begins FTI (tipifarnib) treatment, the addition of other cancer treatment will confound the assessment of efficacy and therefore is not allowed; this restriction precludes the addition of cytotoxic, immunologic agents, radiotherapy, or an increase in corticosteroid dose while the patient is in the treatment phase of this protocol * Known to be human immunodeficiency virus (HIV) positive; HIV testing is not required but should be done if clinically indicated; HIV patients are excluded because of concerns regarding excess risk of complications of immunosuppressive therapy regimens * Known allergy to imidazole drugs such as clotrimazole, ketoconazole, miconazole, econazole, fenticonazole, sulconazole, tioconazole, or terconazole
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants With Confirmed Response (Complete Response, Unconfirmed Complete Response, or Partial Response) During the First 6 Courses of Treatment | During the first 6 cycles of treatment | Confirmed response is at least a 50% decrease in the sum of the products of the greatest diameters (SPD) of the six largest dominant nodes or nodal masses and no increase in the size of other nodes, liver, or spleen and splenic and hepatic nodules must regress by at least 50% in the SPD and no new sites of disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Up to 2 years | Overall survival time was defined as the time from registration to the date of death or last follow-up. |
| Time to Progression | up to 2 years | Time to progression was defined as the number of months from registration to the date of disease progression with patients being progression-free being censored on the date of their last evaluation. Progression is defined as ≥50 % increase from nadir in the SPD of any previously identified abnormal node for partial responders or nonresponders or appearance of any new lesion during or at the end of therapy. |
| Duration of Response | up to 2 years | Duration of response is defined for all evaluable patients that have achieved an objective response as the date at which the patient's objective status is first noted to be either a complete response (CR) or partial response (PR) to the date progression (PD) is documented. CR:Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy PR:≥50% decrease in SPD of the six largest dominant nodes or nodal masses. PD:≥50 % increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders or appearance of any new lesion during or at the end of therapy. |
| Number of Patients Who Experienced Grade 3 or 4 Toxicities | Up to 56 days | Number of patients that experienced a grade 3 or 4 toxicity (adverse events considered at least possibly related to Tipifarnib) as measured by NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) v3.0. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL(Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.). Grade 4: Life-threatening consequences; urgent intervention indicated. |
Countries
United States
Participant flow
Recruitment details
Participants were recruited from 2 medical clinics in the United States between March 2004 to November 2008.
Participants by arm
| Arm | Count |
|---|---|
| Aggressive B-cell NHL Group Patients with aggressive B-cell NHL receive 300mg twice a day for 21 days. Cycle length is 28 days. After cycle 1, may increase the dose to 400mg twice a day or 600mg twice a day at physician discretion. | 42 |
| Indolent B-cell NHL Group Patients with indolent B-cell NHL receive 300mg twice a day for 21 days. Cycle length is 28 days. After cycle 1, may increase the dose to 400mg twice a day or 600mg twice a day at physician discretion. | 15 |
| HL/T-cell Lymphoma Group Patients with HL/T-cell lymphoma receive 300mg twice a day for 21 days. Cycle length is 28 days. After cycle 1, may increase the dose to 400mg twice a day or 600mg twice a day at physician discretion. | 36 |
| Total | 93 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Ineligible | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Aggressive B-cell NHL Group | Indolent B-cell NHL Group | HL/T-cell Lymphoma Group | Total |
|---|---|---|---|---|
| Age, Continuous | 66.5 years | 64.0 years | 48.5 years | 62 years |
| Sex: Female, Male Female | 18 Participants | 10 Participants | 14 Participants | 42 Participants |
| Sex: Female, Male Male | 24 Participants | 5 Participants | 22 Participants | 51 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 34 / 41 | 9 / 15 | 27 / 36 |
| other Total, other adverse events | 38 / 41 | 15 / 15 | 36 / 36 |
| serious Total, serious adverse events | 27 / 41 | 4 / 15 | 20 / 36 |
Outcome results
Primary
Proportion of Participants With Confirmed Response (Complete Response, Unconfirmed Complete Response, or Partial Response) During the First 6 Courses of Treatment
Confirmed response is at least a 50% decrease in the sum of the products of the greatest diameters (SPD) of the six largest dominant nodes or nodal masses and no increase in the size of other nodes, liver, or spleen and splenic and hepatic nodules must regress by at least 50% in the SPD and no new sites of disease.
Time frame: During the first 6 cycles of treatment
Population: All participants are included in this analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Aggressive B-cell NHL Group | Proportion of Participants With Confirmed Response (Complete Response, Unconfirmed Complete Response, or Partial Response) During the First 6 Courses of Treatment | 0.17 Proportion of participants |
| Indolent B-cell NHL Group | Proportion of Participants With Confirmed Response (Complete Response, Unconfirmed Complete Response, or Partial Response) During the First 6 Courses of Treatment | 0.07 Proportion of participants |
| HL/T-cell Lymphoma Group | Proportion of Participants With Confirmed Response (Complete Response, Unconfirmed Complete Response, or Partial Response) During the First 6 Courses of Treatment | 0.31 Proportion of participants |
Secondary
Duration of Response
Duration of response is defined for all evaluable patients that have achieved an objective response as the date at which the patient's objective status is first noted to be either a complete response (CR) or partial response (PR) to the date progression (PD) is documented. CR:Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy PR:≥50% decrease in SPD of the six largest dominant nodes or nodal masses. PD:≥50 % increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders or appearance of any new lesion during or at the end of therapy.
Time frame: up to 2 years
Population: Patients who had a response were included in this analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Aggressive B-cell NHL Group | Duration of Response | 11.3 months |
| Indolent B-cell NHL Group | Duration of Response | 2 months |
| HL/T-cell Lymphoma Group | Duration of Response | 7.5 months |
Secondary
Number of Patients Who Experienced Grade 3 or 4 Toxicities
Number of patients that experienced a grade 3 or 4 toxicity (adverse events considered at least possibly related to Tipifarnib) as measured by NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) v3.0. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL(Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.). Grade 4: Life-threatening consequences; urgent intervention indicated.
Time frame: Up to 56 days
Population: Only eligible participants are included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Aggressive B-cell NHL Group | Number of Patients Who Experienced Grade 3 or 4 Toxicities | 32 Participants |
| Indolent B-cell NHL Group | Number of Patients Who Experienced Grade 3 or 4 Toxicities | 8 Participants |
| HL/T-cell Lymphoma Group | Number of Patients Who Experienced Grade 3 or 4 Toxicities | 24 Participants |
Secondary
Overall Survival
Overall survival time was defined as the time from registration to the date of death or last follow-up.
Time frame: Up to 2 years
Population: All participants are included in this analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Aggressive B-cell NHL Group | Overall Survival | 6.4 months |
| Indolent B-cell NHL Group | Overall Survival | 20.6 months |
| HL/T-cell Lymphoma Group | Overall Survival | 19.7 months |
Secondary
Time to Progression
Time to progression was defined as the number of months from registration to the date of disease progression with patients being progression-free being censored on the date of their last evaluation. Progression is defined as ≥50 % increase from nadir in the SPD of any previously identified abnormal node for partial responders or nonresponders or appearance of any new lesion during or at the end of therapy.
Time frame: up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Aggressive B-cell NHL Group | Time to Progression | 2.8 months |
| Indolent B-cell NHL Group | Time to Progression | 5.2 months |
| HL/T-cell Lymphoma Group | Time to Progression | 3.2 months |